Relmada Therapeutics, Inc. (RLMD) Income Statement
RLMD 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsRLMD revenue and net income
RLMD growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
RLMD quarterly EPS vs estimates
Relmada Therapeutics beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.14).
RLMD income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | — | — | $1,258 | $3,752 | $4,870 | $2,627 | $85,271 | $54,819 |
| Gross profit | — | — | — | — | −$1,258 | −$3,752 | −$4,870 | −$2,627 | −$85,271 | −$54,819 |
| Research & development | $744,560 | $46.2M | $54.8M | $113.3M | $90.6M | $36.0M | $7.9M | $2.9M | $1.3M | $6.2M |
| Sales, general & admin | $311,904 | $37.7M | $48.9M | $47.9M | $35.1M | $24.9M | $7.2M | $4.0M | $5.9M | $10.1M |
| Total operating expenses | $59.1M | $83.9M | $103.7M | $161.2M | $125.7M | $60.8M | $15.1M | $6.9M | $7.2M | $16.2M |
| Operating income | −$59.1M | −$83.9M | −$103.7M | −$161.2M | −$125.7M | −$60.8M | −$15.1M | −$6.9M | −$7.2M | −$16.2M |
| Interest income | $1.4M | $3.5M | $5.2M | $2.7M | $1.2M | $1.4M | — | — | — | — |
| Interest expense | — | — | — | $4.2M | $48,317 | $1.4M | — | $1.3M | $550 | — |
| Income before taxes | −$57.4M | −$80.0M | −$98.8M | −$157.0M | −$125.8M | −$59.5M | −$15.0M | −$9.0M | −$6.3M | −$3.0M |
| Income taxes | — | — | −$103,702 | −$2.7M | $48,317 | −$1.4M | $4.6M | $2.0M | −$716,000 | −$13.1M |
| Net income | −$57.4M | −$80.0M | −$98.8M | −$157.0M | −$125.8M | −$59.5M | −$15.0M | −$9.0M | −$6.3M | −$3.0M |
| EBITDA | −$57.4M | −$80.0M | $4.9M | −$157.0M | −$125.8M | −$59.3M | −$15.1M | −$6.9M | −$6.9M | −$16.0M |
| EPS (diluted) | −$1.47 | −$2.65 | −$3.28 | −$5.15 | −$7.08 | −$3.83 | −$1.35 | −$1.08 | −$1.95 | −$2.49 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $8.4M | $8.1M | $8.1M | $4.0M | $2.8M | $12.0M | $11.0M | $11.1M | $10.7M | $13.3M | $14.8M | $10.5M |
| Sales, general & admin | $6.6M | $11.4M | $12.3M | $6.3M | $7.4M | $6.3M | $8.1M | $11.9M | $8.1M | $9.7M | $12.1M | $12.2M |
| Total operating expenses | $15.0M | $19.5M | $20.3M | $10.3M | $10.2M | $18.2M | $19.1M | $23.0M | $18.8M | $23.0M | $26.8M | $22.7M |
| Operating income | −$15.0M | −$19.5M | −$20.3M | −$10.3M | −$10.2M | −$18.2M | −$19.1M | −$23.0M | −$18.8M | −$23.0M | −$26.8M | −$22.7M |
| Interest income | $2.3M | $959,762 | $387,231 | $247,013 | $321,458 | $440,287 | $654,642 | $856,478 | $963,013 | $1.1M | $1.3M | $1.3M |
| Income before taxes | −$12.9M | −$19.1M | −$19.9M | −$10.1M | −$9.9M | −$17.6M | −$18.7M | −$21.7M | −$17.8M | −$21.8M | −$25.2M | −$22.0M |
| Income taxes | — | — | — | — | — | — | — | — | −$18.8M | −$23.0M | −$26,829 | −$1.3M |
| Net income | −$12.9M | −$19.1M | −$19.9M | −$10.1M | −$9.9M | −$17.6M | −$18.7M | −$21.7M | −$17.8M | −$21.8M | −$25.2M | −$22.0M |
| EBITDA | −$12.9M | −$19.1M | −$19.9M | −$10.1M | −$9.9M | −$17.6M | $418,418 | $1.3M | $1.1M | −$21.8M | $1.7M | −$22.0M |
| EPS (diluted) | −$0.11 | −$0.22 | −$0.29 | −$0.30 | −$0.30 | −$0.58 | −$0.62 | −$0.72 | −$0.59 | −$0.72 | −$0.84 | −$0.73 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in RLMD's financial statements (latest annual report filed March 19, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
RLMD financial results
Relmada Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $57.4 million. Diluted earnings per share came to −$1.47.
See the RLMD stock overview for the latest quote and news, or the RLMD chart for price history and technical indicators.
RLMD income statement FAQ
Does Relmada Therapeutics have revenue?
Relmada Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Relmada Therapeutics profitable?
No. Relmada Therapeutics reported a net loss of $57.4 million in fiscal 2025.
How much does Relmada Therapeutics spend on research and development?
Relmada Therapeutics spent $0.7 million on research and development in fiscal 2025.
What are Relmada Therapeutics's earnings per share?
Relmada Therapeutics earned $-1.47 per diluted share in fiscal 2025, compared with $-2.65 a year earlier.
When will Relmada Therapeutics report its next earnings?
Relmada Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes.
When does Relmada Therapeutics's fiscal year end?
Relmada Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 19, 2026.